Phaseline

Companies › BioTheraVision

BioTheraVision: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BTV100 Low dose (1% Cevimeline Ophthalmic Solution)
M3 muscarinic receptor agonist
M3Phase 2Dry Eye–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06543303BTV100 Low dose (1% Cevimeline Ophthalmic Solution)Phase 2Dry EyeOphthalmologyJan 2026
NCT06543303BTV100 Low dose (1% Cevimeline Ophthalmic Solution)Phase 2Dry EyeOphthalmologyJan 2026
NCT06543303BTV100 Low dose (1% Cevimeline Ophthalmic Solution)Phase 2Dry EyeOphthalmologyJan 2026

Targets

M3 (1)

Companies with the same targets

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical

Companies built like this

Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical ONL Therapeutics Vantage Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.